Physician profile
Mark Breazzano
NPI 1619388121
$29,754.64
in general payments reported to CMS, 2019-2025
7 companies · $13K in 2025
The $13K reported for 2025 was more than what 92% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,736 · 2023: $15K · 2024: $144 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Consulting Fee: $13K · Travel and Lodging: $1,144 · Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,200.00 |
| Consulting Fee | $12,960.00 |
| Travel and Lodging | $1,143.89 |
| Food and Beverage | $714.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $15,016.20 | 2023-2024 | Izervay |
| Qiagen, LLC | $9,900.00 | 2025 | |
| Neurotech Pharmaceuticals, INC. | $3,060.00 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $1,466.69 | 2019 | |
| Dutch Ophthalmic, USA | $144.79 | 2019 | |
| Alcon Vision LLC | $124.41 | 2019 | |
| Alimera Sciences, INC. | $42.55 | 2024 | Iluvien, Yutiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Breazzano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.